Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Frequently asked questions
What sector does Dyne Therapeutics Inc (DYN) operate in?
Dyne Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Dyne Therapeutics Inc (DYN) current stock price?
As of the latest data, Dyne Therapeutics Inc stock price is $26.00, with a previous close of $26.15. Dyne Therapeutics Inc lost -$0.15 in the last trading session, representing a -0.57% loss.
What is Dyne Therapeutics Inc (DYN) current market capitalization?
Dyne Therapeutics Inc market cap is approximately 4.85 billion.
What is Dyne Therapeutics Inc (DYN) Earnings Per Share (EPS)?
The trailing EPS is -$3.15, and the forward EPS is -$2.93.
What is Dyne Therapeutics Inc (DYN) EBITDA?
Dyne Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -181.66 million.
Does Dyne Therapeutics Inc (DYN) pay dividends?
No. Dyne Therapeutics Inc does not pay a dividend.
What is Dyne Therapeutics Inc (DYN) beta (volatility) score?
Dyne Therapeutics Inc has a beta of 1.057, meaning its volatility is roughly in line with the market.
